Dosimetry in Theranostics

Quick Answer

Dosimetry estimates the radiation absorbed dose (in gray, Gy) delivered to tumors and to normal organs at risk during radioligand therapy. The standard framework is MIRD, which combines the time-integrated activity in a region (how much isotope is there and for how long) with tissue-specific dose factors. For Lu-177 therapies, serial post-therapy SPECT/CT (using Lu-177's imageable gammas) enables patient-specific dosimetry; the kidneys, salivary glands, and bone marrow are the principal organs at risk.

Why it matters

Radioligand therapy can be delivered as fixed activity (the common regulatory-approved approach, e.g. 7.4 GBq per cycle) or dosimetry-guided (tailoring activity to keep organs at risk under threshold while maximizing tumor dose). Dosimetry supports safety (avoiding renal/marrow toxicity), may allow more cycles or higher activity in tolerant patients, and is increasingly expected for personalized therapy and trials.

The MIRD framework (conceptually)

Absorbed dose to a target region = time-integrated activity in source regions × S-values (dose per unit cumulated activity, specific to the isotope and the source→target geometry).

The two inputs:

1. Time-integrated activity (cumulated activity): how much activity accumulates in a region and how long it stays — obtained from serial imaging at several time points to build a time–activity curve, then integrated.
2. S-value / dose factor: the physical conversion from cumulated activity to dose for a given isotope and anatomy (reference phantoms or, better, patient-specific voxel dosimetry).

Data acquisition

• Lu-177 (β⁻ + γ): quantitative SPECT/CT at multiple post-therapy time points; the imageable gamma makes true patient-specific dosimetry feasible.
• Y-90 (pure β): bremsstrahlung SPECT or Y-90 PET (exploiting the small internal pair-production branch) to verify distribution; quantitative dosimetry is harder than for Lu-177.
• Alpha emitters (Ac-225): direct imaging is very difficult; dosimetry relies on surrogate imaging and models.

Organs at risk

Dose = time-integrated activity × S-value

The MIRD framework computes absorbed dose (gray) from two inputs: time-integrated activity (how much isotope is in a region and for how long — from serial imaging) times the S-value (isotope- and geometry-specific dose per unit cumulated activity). Fixed-activity regimens dominate approved practice, but dosimetry-guided dosing personalizes therapy and can allow more cycles in tolerant patients.

Lu-177's built-in advantage, and the organs at risk

Lu-177's imageable gamma lets every therapy cycle double as a post-therapy SPECT/CT dosimetry scan — a quality check pure-beta (Y-90) and alpha (Ac-225) emitters lack. Dose-limiting organs differ by agent: kidneys/salivary (PSMA), kidneys/marrow (DOTATATE), marrow (Ra-223), liver/lungs (Y-90) — and renal dose is cumulative across cycles.

The accuracy nuances

Single-time-point imaging poorly estimates time-integrated activity; multi-time-point sampling is more accurate. Reference-phantom S-values can misestimate dose in atypical anatomy — voxel-based methods are preferred where available. Y-90 dosimetry relies on bremsstrahlung SPECT or the small internal-pair-production PET signal; alpha-emitter dosimetry is hardest because directly imaging alphas is difficult. Lesional dosimetry (I-124 PET) supports a ~85 Gy response threshold that empiric activities often miss in bone.

High-Yield Pearls

• Lu-177's gamma emission is a built-in advantage: every therapy cycle can double as a dosimetry and quality-assurance scan.
• Renal dose is cumulative — amino acid infusion (DOTATATE) reduces renal retention; track function across cycles.

Common Pitfalls

• Single-time-point imaging poorly estimates the time-integrated activity; multi-time-point sampling is more accurate.
• Applying reference-phantom S-values to patients with atypical anatomy can misestimate dose — voxel-based methods are preferred where available.

Self-Check

Key References

• MIRD Committee pamphlets, SNMMI.
• EANM dosimetry committee guidance for ¹⁷⁷Lu-labeled radioligand therapy.